Rheumatology

Article	Citations
Treatment guidelines in psoriatic arthritis	108
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study	97
Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series	97
Lupus nephritis: clinical presentations and outcomes in the 21st century	95
Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark	92
Osteosarcopenia: where osteoporosis and sarcopenia collide	87
COVID-19 vaccination and antirheumatic therapy	86
IgG4-related disease: a clinical perspective	79
Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment	78
The genetics of rheumatoid arthritis	75
Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors	75
Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease	71
Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis	69
An update on the epidemiology of ANCA-associated vasculitis	68
A roadmap to target interleukin-6 in osteoarthritis	68
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs	68
Behçet: the syndrome	64
A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies	64
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients	63
VEXAS syndrome in a woman	62
Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis	59
Genetics and epigenetics in primary Sjögren’s syndrome	59
Rituximab in the treatment of systemic sclerosis–related interstitial lung disease: a systematic review and meta-analysis	59
The safety of JAK-1 inhibitors	58
Diagnosis of giant cell arteritis	57

Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis	55
Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease	55
Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis	54
Sex and gender differences in axial spondyloarthritis: myths and truths	54
Telemedicine in rheumatology: a reliable approach beyond the pandemic	53
Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management	51
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19	50
Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017	50
The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?	50
Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls	50
Treatment of Sjögren’s syndrome: current therapy and future directions	50
Classifying and diagnosing systemic lupus erythematosus in the 21st century	49
Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis	49
Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis	49
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus	46
Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes	45
Correlation between pain severity and levels of anxiety and depression in osteoarthritis patients: a systematic review and meta-analysis	45
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study	45
Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study	44
A case of psoriatic arthritis triggered by SARS-CoV-2 infection	44
Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis	43
Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease	43
Management of Behcet’s syndrome	43
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials	41
Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines	41
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis	41
Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility	41
Prevalence, incidence and cause-specific mortality of rheumatoid arthritis–associated interstitial lung disease among older rheumatoid arthritis patients	41
Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2)	40
Atypical splice-site mutations causing VEXAS syndrome	40
An association between chronic widespread pain and the gut microbiome	40
Temporal relationship between osteoarthritis and comorbidities: a combined case control and cohort study in the UK primary care setting	40
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study	40
Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians	40
VEXAS syndrome: still expanding the clinical phenotype	39
Association between environmental air pollution and rheumatoid arthritis flares	39
Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic	39
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study	39
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study	38
Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice	38
Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study	38
Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus	38
Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis	38
The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis	38
Acute exacerbation of rheumatoid arthritis–associated interstitial lung disease: clinical features and prognosis	38
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccin	37
Treatment strategies in axial spondyloarthritis: what, when and how?	37
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies	37
The cut-off values for the intima–media complex thickness assessed by colour Doppler sonography in seven cranial and aortic arch arteries	37
Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties	37

COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries	36
Rhabdomyolysis as the main manifestation of coronavirus disease 2019	36
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis	36
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries	36
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions	35
Predicting response to topical non-steroidal anti-inflammatory drugs in osteoarthritis: an individual patient data meta-analysis of randomized controlled trials	35
British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy	35
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial	35
Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study	35
Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection	35
IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts	35
Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients	34
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis	34
COVID-19 and myositis – unique challenges for patients	34
Comorbidities in ANCA-associated vasculitis	34
Glycine increased ferroptosis via SAM-mediated GPX4 promoter methylation in rheumatoid arthritis	34
Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis	34
VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy	34
Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy	34
Whole-body MRI in the diagnosis of paediatric CNO/CRMO	34
Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status	33
New biomarkers in SLE: from bench to bedside	33
Socioeconomic status and occurrence of chronic pain: a meta-analysis	33
Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis	33
IL-37 inhibits M1-like macrophage activation to ameliorate temporomandibular joint inflammation through the NLRP3 pathway	32
Tele-rheumatology for overcoming socioeconomic barriers to healthcare in resource constrained settings: lessons from COVID-19 pandemic	32
Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjögren’s syndrome	32
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort	32
Circulating adiponectin levels and systemic lupus erythematosus: a two-sample Mendelian randomization study	32
Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population	31
A case of VEXAS syndrome manifesting as Kikuchi-Fujimoto disease, relapsing polychondritis, venous thromboembolism and macrocytic anaemia	31
The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance	31
Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma	31
Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study	31
Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis	31
Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy	30
A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition	30
Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis	30
Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study	29
Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study	29
All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study	29
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice	29
Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash	29
The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study	29
Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database	29
Axial spondyloarthritis 10 years on: still looking for the lost tribe	28
Comorbidities (excluding lymphoma) in Sjögren’s syndrome	28
JAK1: Number one in the family; number one in inflammation?	28
Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria	28
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications	28
Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease	28
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids	27
A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis	27
Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis	27
Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach	27
Systemic autoimmune disease as a cause of death: mortality burden and comorbidities	27
P105 Prevalence and associated factors of musculoskeletal joint disease in the community setting in Hai district, northern Tanzania	27
Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience	27
Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis	27
Retinal microcirculation abnormalities in patients with systemic sclerosis: an explorative optical coherence tomography angiography study	27
Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases	27
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice	26
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study	26
Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica	26
The iCanCope pain self-management application for adolescents with juvenile idiopathic arthritis: a pilot randomized controlled trial	26
A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment	26
Diagnostic value of axillary artery ultrasound in patients with suspected giant cell arteritis	26
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis	26
The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease	26
Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre	26
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs	26
Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis	25
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parall	25
Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study	25
Towards sex-specific osteoarthritis risk models: evaluation of risk factors for knee osteoarthritis in males and females	25
Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis	25
Femoral vein wall thickness measurement: A new diagnostic tool for Behçet’s disease	25
JAK1 inhibition and inflammatory bowel disease	25
PKM2-dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis/polymyositis	25
Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis	25

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis	25
Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study	25
Patient-based reliability of the Outcome Measures in Rheumatology (OMERACT) ultrasound scoring system for salivary gland assessment in patients with Sjögren’s syndrome	24
Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis	24
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review	24
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension	24
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome	24
The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study	24
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients	24
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review	24
Treatment targets in SLE: remission and low disease activity state	24
Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases	24
Childhood-onset of primary Sjögren’s syndrome: phenotypic characterization at diagnosis of 158 children	23
Long-term outcome after perineural injection with 5% dextrose for carpal tunnel syndrome: a retrospective follow-up study	23
Causal relationship of serum nutritional factors with osteoarthritis: a Mendelian randomization study	23
Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series	23
Frugoside delays osteoarthritis progression via inhibiting miR-155-modulated synovial macrophage M1 polarization	23
Joint anatomy in axial spondyloarthritis: strong associations between sacroiliac joint form variation and symptomatic disease	23
New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study	23
Metabolomic profiling reveals serum L-pyroglutamic acid as a potential diagnostic biomarker for systemic lupus erythematosus	23
Neutrophil extracellular traps mediate joint hyperalgesia induced by immune inflammation	23
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis	23
Current and emerging biological therapy in adult-onset Still’s disease	23
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway	23
Tofacitinib in patients with refractory Takayasu’s arteritis	23
Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility	22
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	22
Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease	22
Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America	22
Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still’s disease	22
Dissecting the clinical heterogeneity of adult-onset Still’s disease: results from a multi-dimensional characterization and stratification	22
Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study	22
Splicing factor SRSF1 controls T cell homeostasis and its decreased levels are linked to lymphopenia in systemic lupus erythematosus	22
Glucocorticoid use is associated with an increased risk of hypertension	22
Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants	22
Are neutrophil extracellular traps the link for the cross-talk between periodontitis and rheumatoid arthritis physiopathology?	22
High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India	22
Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): updated picture from a French multicentre and retrospective series of 260 cases	22
The patient’s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?	22
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	22
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis	22
Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management	22
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study	22
Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren’s syndrome	22
Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus	21
A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever	21
Deep learning algorithms for magnetic resonance imaging of inflammatory sacroiliitis in axial spondyloarthritis	21
Clonal haematopoiesis is increased in early onset in systemic sclerosis	21
A systematic review and meta-analysis of the incidence rate of Takayasu arteritis	21
Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic	21
Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis	21
Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000–2018: results from the Clinical Practice Research Datalink	21
Identification of the urine and serum metabolomics signature of gout	21
New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation	21
Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis	21
Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus	21
Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS	21
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)	21
Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?—observations from the UK JSLE Cohort Study	21
Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study	20
Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia	20
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype	20
Identification and characterization of two consistent osteoarthritis subtypes by transcriptome and clinical data integration	20
Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis	20
Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA	20
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study	20
Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study	20
Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studie	20
Behçet’s-like adverse event or inaugural Behçet’s disease after SARS-CoV-2 mRNA-1273 vaccination?	20
LncRNA-H19 silencing suppresses synoviocytes proliferation and attenuates collagen-induced arthritis progression by modulating miR-124a	20
Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis	20
Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response	20
Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)	20
Prevalence of anxiety and depression in patients with rheumatoid arthritis before and during the COVID-19 pandemic	20
Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout	20
Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)	20
Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses’ Health Study	20
Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study	20
US rheumatologists’ beliefs and knowledge about biosimilars: a survey	20
P208 A retrospective survey of arthritis among inpatients at a consultant hospital in Northern Tanzania from 2017 to 2019	20
STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis	20
A new diagnosis of systemic capillary leak syndrome in a patient with COVID-19	20
Multi-energy photon-counting computed tomography versus other clinical imaging techniques for the identification of articular calcium crystal deposition	19
Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study	19
Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search	19
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study	19
Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra	19
Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes	19
Circular RNA sequencing indicates circ-IQGAP2 and circ-ZC3H6 as noninvasive biomarkers of primary Sjögren’s syndrome	19
Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: results from a harmonized dataset (1981–2021)	19
Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry	19
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual	19
A dysregulated interleukin-18–interferon-γ–CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis	19
Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience	19
Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150 000 routine computed tomography scans	19